Organometallics
Article
(
16) Yi, S.; Li, W.; Nieto, D.; Cuadrado, I.; Kaifer, A. E. Org. Biomol.
(30) For references on related ferrocene-containing amidines and
amidinates see, for example: (a) Hagadorn, J. R.; Arnold, J. J.
Organomet. Chem. 2001, 637−639, 521−530. (b) Coles, M. P.; Stokes,
F. A.; Kingsbury, B. F. K.; Day, B. M.; Hitchcock, P. B. Cryst. Growth
Des. 2011, 11, 3206−3212. (c) Stokes, F. A.; Coles, M. P.; Hitchcock,
P. B. CrystEngComm 2012, 14, 771−773. See also ref 26.
(31) Wu, X.-F.; Neumann, H. Adv. Synth. Catal. 2012, 354, 3141−
3160.
(32) Recent examples of Pt(II)−guanidine complexes have been
reported; see, for example: (a) Legin, A. A.; Jakupec, M. A.; Bokach, N.
A.; Tyan, M. R.; Kukushkin, V. Y.; Keppler, B. K. J. Inorg. Biochem.
2014, 133, 33−39. (b) Tyan, M. R.; Bokach, N. A.; Wang, M. J.;
Haukka, M.; Kuznetsov, M. L.; Kukushkin, V. K. Dalton Trans. 2008,
5178−5188.
(33) Still, B. M.; Kumar, P. G.; Aldrich-Wright, J. R.; Price, W. S.
Chem. Soc. Rev. 2007, 36, 665−686.
(34) Elumalai, P.; Thirupathi, N.; Nethaji, M. Inorg. Chem. 2013, 52,
Chem. 2013, 11, 287−293.
(
(
Pavlov, V.; Daum, S.; Mokhir, A. J. Med. Chem. 2013, 56, 6935−6944.
(
17) Kaifer, A. E. Acc. Chem. Res. 2014, 47, 2160−2167.
18) Marzenell, P.; Hagen, H.; Sellner, L.; Zenz, T.; Grinyte, R.;
19) For reviews on the anticancer and biomedical applications of
ferrocene derivatives see, for example: (a) Braga, S. S.; Silva, A. M. S.
Organometallics 2013, 32, 5626−5639. (b) Hartinger, C. G.; Metzler-
Nolte, N.; Dyson, P. J. Organometallics 2012, 31, 5677−5685. (c) van
Staveren, D. R.; Metzler-Nolte, N. Chem. Rev. 2004, 104, 5931−5985.
(
d) Gasser, G.; Ott, I.; Metzler-Nolte, N. J. Med. Chem. 2011, 54, 3−
5. (e) Ornelas, C. New J. Chem. 2011, 35, 1973−1985. (f) Hartinger,
2
C.; Dyson, P. J. Chem. Soc. Rev. 2009, 38, 391−401. Bioorganometallics:
Biomolecules, Labeling, Medicine;(g) Jaouen, G., Ed.; Wiley-VCH:
Weinheim, Germany, 2006. (h) Salmain, M.; Metzler-Nolte, N.
Bioorganometallic Chemistry of Ferrocene. In Ferrocenes: Ligands,
Materials and Biomolecules, Step
008; pp 499−639.
20) For recent examples of heterometallic Fc−Pt compounds, see:
a) Cortes, R.; Tarrado-Castellarnau, M.; Talancon, D.; Lopez, C.;
̀
nicka, P., Ed.; Wiley: Chichester, U.K.,
1
(
883−1894.
35) Montero, E.; Díaz, S.; Gonzal
Alonso, C.; Navarro-Ranninger, C. J. Med. Chem. 1999, 42, 4264−
268.
36) Bard, A. J.; Faulkner, L. R. Electrochemical Methods:
Fundamentals and Applications, 2nd ed.; Wiley: New York, 2001.
37) Inorganic Electrochemistry. Theory, Practice and Application;
2
(
́ ́
ez-Vadillo, A. M.; Perez, J. M.;
(
́
́
́
4
(
Link, W.; Ruiz, D.; Centelles, J. J.; Quirante, J.; Cascante, M.
Metallomics 2014, 6, 622−633. (b) Schulz, J.; Renfrew, A. K.; Cisarova,
̌
I.; Dyson, P. J.; Step
97. (c) Banfic,
B. K. Eur. J. Inorg. Chem. 2014, 2014, 484−492. See also ref 27.
21) For heterometallic Fc−Pd compounds, see for example:
a) Lease, N.; Vasilevski, V.; Carreira, M.; de Almeida, A.; Sanau,
̌ ̌
nicka, P. Appl. Organomet. Chem. 2010, 24, 392−
(
3
́
J.; Legin, A. A.; Jakupec, M. A.; Galanski, M.; Keppler,
Zanello, P., Nervi, C., Fabrizi de Biani, F., Eds.; Royal Society of
Chemistry: Cambridge, U.K., 2013.
(
(
38) Emilia, M.; Pombeiro, A. J. L.; da Silva, J. F.; Herrmann, R.;
Deus, N.; Castilho, T. J.; Silva, M. F. J. Organomet. Chem. 1991, 421,
5−90.
39) A related example of a particularly electron rich 1,1′-
(
M.; Hirva, P.; Casini, A.; Contel, M. J. Med. Chem. 2013, 56, 5806−
7
5
4
(
818. (b) Caires, A. C. F. Anti-Cancer Agents Med. Chem. 2007, 7,
84−491.
(
5
disubstituted diaminoferrocene is fc(DMP)2 (fc = Fe(η -C H ) ,
22) For heterometallic Fc−Au compounds, see, for example:
5
4 2
DMP = 2,5-dimethylpyrrolidinyl). See ref 11b.
40) (a) Strehler, F.; Korb, M.; Poppitz, E. A.; Lang, H. J. Organomet.
(
a) Goitia, H.; Nieto, Y.; Villacampa, M. D.; Kasper, C.; Laguna, A.;
Gimeno, M. C. Organometallics 2013, 32, 6069−6078. (b) Gimeno, M.
C.; Goitia, H.; Laguna, A.; Luque, M. E.; Villacampa, M. D.; Sepulveda,
C.; Meireles, M. J. J. Inorg. Biochem. 2011, 105, 1373−1382. (c) Fourie,
E.; Erasmus, E.; Swarts, J. C.; Jakob, A.; Lang, H.; Joone, G. K.; van
Rensburg, C. E. J. Anticancer Res. 2011, 31, 825−830. (d) Schulz, J.;
Tauchman, J.; Císaro
Organomet. Chem. 2014, 751, 604−609.
(
(
Chem. 2015, 786, 1−9. (b) Osakada, K.; Sakano, T.; Horie, M.; Suzaki,
́
Y. Coord. Chem. Rev. 2006, 250, 1012−1022.
(41) For recent reviews on platinum anticancer agents, see for
example: (a) Johnstone, T. C.; Wilson, J. J.; Lippard, S. J. Inorg. Chem.
̌
2013, 52, 12234−12249. (b) Wilson, J. J.; Lippard, S. J. Chem. Rev.
̌
va,
́
I.; Riedel, T.; Dyson, P. J.; Step
̌
nick
̌
a, P. J.
2
014, 114, 4470−4495. (c) Reedijk, J. Eur. J. Inorg. Chem. 2009, 2009,
1
303−1312. (d) Casini, A.; Reedijk, J. Chem. Sci. 2012, 3, 3135−3144.
23) For heterometallic Fc−Ru compounds, see for example:
(
42) Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.;
̌
̌ ̌
nicka, P.; Zava, O.; Dyson, P.
(
a) Tauchman, J.; Suss-Fink, G.; Step
J. J. Organomet. Chem. 2013, 723, 233−238. (b) Auzias, M.; Therrien,
B.; Suss-Fink, G.; Stepnicka, P.; Ang, W. H.; Dyson, P. J. Inorg. Chem.
008, 47, 578−583.
24) Cuadrado, I. In Silicon-Containing Dendritic Polymers; Dvornic,
P., Owen, M. J., Eds.; Springer: Berlin, 2009; pp 141−196.
25) (a) Enríquez, A.; Gonzalez-Vadillo, A. M.; Martínez-Montero, I.;
Bruna, S.; Leemans, L.; Cuadrado, I. Organometallics 2014, 33, 7307−
317. (b) Bruna, S.; Nieto, D.; Gonzalez-Vadillo, A. M.; Perles, J.;
Cuadrado, I. Organometallics 2012, 31, 3248−3258. (c) Bruna, S.;
Gonzalez-Vadillo, A. M.; Nieto, D.; Pastor, C. J.; Cuadrado, I.
Macromolecules 2012, 45, 781−793. (d) Bruna, S.; Gonzalez-Vadillo,
A. M.; Nieto, D.; Pastor, C. J.; Cuadrado, I. Organometallics 2010, 29,
796−2807. (e) Nieto, D.; Bruna, S.; Montero-Campillo, M. M.;
Gonzalez-Vadillo, A. M.; Mendez, J.; Mo, O.; Cuadrado, I. Chem.
Commun. 2013, 49, 9785−9787.
26) Nieto, D.; Gonzalez-Vadillo, A. M.; Brun
Kaifer, A. E.; Cuadrado, I. Chem. Commun. 2011, 47, 10398−10400.
27) Nieto, D.; Gonzalez-Vadillo, A. M.; Bruna, S.; Pastor, C. J.; Ríos-
Luci, C.; Leon, L. G.; Padron, J. M.; Navarro-Ranninger, C.; Cuadrado,
I. Dalton Trans. 2012, 41, 432−441.
28) (a) Oton, F.; Espinosa, A.; Tar
Molina, P. Chem. - Eur. J. 2007, 13, 5742−5752. (b) Oton
A.; Molina, P. Org. Lett. 2006, 8, 2107−2110. (c) Sola, A.; Tar
Molina, P. Dalton Trans. 2012, 41, 8401−8409.
29) (a) Klapp, L. R. R.; Bruhn, C.; Leibold, M.; Siemeling, U.
Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-
Goodrich, M.; Campbell, H.; Boyd, M. J. Natl. Cancer Inst. 1991, 83,
̌
̌
7
57−766.
43) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv.
Drug Delivery Rev. 2001, 46, 3−26.
44) Price, J. H.; Williamson, A. N.; Schramm, R. F.; Wayland, B. B.
Inorg. Chem. 1972, 11, 1280−1284.
45) Sheldrick, G. M. SADABS Version 2.03, Program for Empirical
Absorption Correction; University of Gottingen, Gottingen, Germany,
997−2001.
46) SAINT+NT Version 6.04, SAX Area-Detector Integration Program;
Bruker Analytical X-ray Instruments, Madison, WI, 1997−2001.
47) SHELXTL Version 6.10, Structure Determination Package; Bruker
Analytical X-ray Instruments, Madison, WI, 2000.
48) Sheldrick, G. M. Acta Crystallogr., Sect. A: Found. Crystallogr.
990, 46, 467.
49) Sheldrick, G. M. SHELXL97, Program for Crystal Structure
Refinement; University of Gottingen, Gottingen, Germany, 1997.
50) Miranda, P. O.; Padron, J. M.; Padron, J. I.; Villar, J.; Martín, V.
S. ChemMedChem 2006, 1, 323−329.
2
(
(
(
(
́
̃
(
7
̃
́
̈
̈
̃
1
́
(
̃
́
(
2
̃
́
́
(
1
(
(
́
̃
a, S.; Pastor, C. J.;
̈
̈
(
́
̃
(
́
́
́
́
(
́
́
raga, A.; Ramírez de Arellano, C.;
, F.; Tarraga,
raga, A.;
́
́
́
(
Organometallics 2013, 32, 5862−5872. (b) Gul, R.; Rauf, M. K.;
Badshah, A.; Sikander, A.; Muhammad, A.; Tahir, N.; Khan, A. Eur. J.
Med. Chem. 2014, 85, 438−449.
5
417
Organometallics 2015, 34, 5407−5417